HHS moves to ease testosterone rules as evidence reshapes risk picture

US health officials want updated labeling for testosterone replacement therapy to reflect newer evidence that cardiovascular risks may be smaller than once feared, potentially easing access for older men; the TRAVERSE trial showed no excess major cardiac events but higher rates of atrial fibrillation and pulmonary embolism, and experts remain divided on prostate cancer risk, with labeling suggestions to limit use in metastatic cases and require ongoing monitoring for benign prostatic hyperplasia.